LLY

966.05

+1.94%↑

JNJ

221.47

+0.16%↑

ABBV

202.89

+0.87%↑

UNH

384.38

+1.3%↑

AZN

181.75

-0.31%↓

LLY

966.05

+1.94%↑

JNJ

221.47

+0.16%↑

ABBV

202.89

+0.87%↑

UNH

384.38

+1.3%↑

AZN

181.75

-0.31%↓

LLY

966.05

+1.94%↑

JNJ

221.47

+0.16%↑

ABBV

202.89

+0.87%↑

UNH

384.38

+1.3%↑

AZN

181.75

-0.31%↓

LLY

966.05

+1.94%↑

JNJ

221.47

+0.16%↑

ABBV

202.89

+0.87%↑

UNH

384.38

+1.3%↑

AZN

181.75

-0.31%↓

LLY

966.05

+1.94%↑

JNJ

221.47

+0.16%↑

ABBV

202.89

+0.87%↑

UNH

384.38

+1.3%↑

AZN

181.75

-0.31%↓

Search

Quidel Corp

Atvērts

10.02 -6.62

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

10.11

Max

10.81

Galvenie mērījumi

By Trading Economics

Ienākumi

602M

-131M

Pārdošana

24M

724M

Peļņas marža

-18.062

Darbinieki

6,500

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+11.39% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 4. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-509M

700M

Iepriekšējā atvēršanas cena

16.64

Iepriekšējā slēgšanas cena

10.02

Quidel Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. maijs 23:47 UTC

Tirgus saruna

Gold Falls on Renewed Inflation Concerns -- Market Talk

2026. g. 10. maijs 23:44 UTC

Tirgus saruna

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2026. g. 10. maijs 23:38 UTC

Tirgus saruna

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

2026. g. 10. maijs 23:14 UTC

Tirgus saruna

Australia's Political Map Continues to Be Redrawn -- Market Talk

2026. g. 10. maijs 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Elevra Lithium: Expects Deal to Close in 1Q FY27

2026. g. 10. maijs 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

2026. g. 10. maijs 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

2026. g. 10. maijs 10:21 UTC

Peļņas

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

2026. g. 9. maijs 06:05 UTC

Peļņas

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

2026. g. 8. maijs 23:55 UTC

Peļņas

Review & Preview: Still Going Strong -- Barrons.com

2026. g. 8. maijs 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 8. maijs 20:49 UTC

Peļņas

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

2026. g. 8. maijs 20:25 UTC

Peļņas

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026. g. 8. maijs 19:43 UTC

Peļņas

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

2026. g. 8. maijs 19:43 UTC

Peļņas

Cencosud 1Q Net $115M

2026. g. 8. maijs 19:20 UTC

Tirgus saruna

Oil Futures End Session Higher, But Down on the Week -- Market Talk

2026. g. 8. maijs 19:18 UTC

Peļņas

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

2026. g. 8. maijs 19:16 UTC

Peļņas

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026. g. 8. maijs 19:08 UTC

Peļņas

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026. g. 8. maijs 19:05 UTC

Peļņas

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

2026. g. 8. maijs 19:02 UTC

Tirgus saruna

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

2026. g. 8. maijs 18:51 UTC

Peļņas

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

2026. g. 8. maijs 18:49 UTC

Peļņas

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026. g. 8. maijs 18:41 UTC

Peļņas

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

2026. g. 8. maijs 17:38 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

2026. g. 8. maijs 17:14 UTC

Peļņas

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

2026. g. 8. maijs 17:04 UTC

Tirgus saruna

Zcash Caps Off Parabolic Week -- Market Talk

2026. g. 8. maijs 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 8. maijs 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 8. maijs 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Quidel Corp Prognoze

Cenas mērķis

By TipRanks

11.39% augšup

Prognoze 12 mēnešiem

Vidējais 12.03 USD  11.39%

Augstākais 13 USD

Zemākais 11 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Quidel Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

6 ratings

1

Pirkt

4

Turēt

1

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

Pamatdarbības peļņa

$

Par Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat